1 Research Letter

2 Do COVID-19 patients admitted to the ICU require anti-*Pneumocystis jirovecii* prophylaxis?

3

4 Alexandre Alanio, M.D., Ph.D.*

5 Laboratoire de Parasitologie-Mycologie AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-

6 Vidal, Université de Paris, and Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National

7 de Référence Mycoses Invasives et Antifongiques, URA3012, Paris, France

8

9 Sebastian Voicu, M.D., Ph.D.

10 Réanimation Médicale et Toxicologique, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-

11 Vidal, Université de Paris, INSERM UMRS1144, Paris, France

12

13 Sarah Dellièvre, M.D.

14 Laboratoire de Parasitologie-Mycologie AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-

15 Vidal, Université de Paris, and Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National

16 de Référence Mycoses Invasives et Antifongiques, URA3012, Paris, France

17

18 Bruno Mégarbane, M.D., Ph.D.

19 Réanimation Médicale et Toxicologique, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-

20 Vidal, Université de Paris, INSERM UMRS1144, Paris, France

21

22 Stéphane Bretagne, M.D., Ph.D.

23 Laboratoire de Parasitologie-Mycologie AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-

24 Vidal, Université de Paris, and Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National

25 de Référence Mycoses Invasives et Antifongiques, URA3012, Paris, France

26

27 *Corresponding author (e-mail : alexandre.alanio@aphp.fr).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 **Author Contributions:**

29 *Concept and design:* Alanio, Mégarbane, Bretagne

30 *Patient care:* Voicu, Mégarbane.

31 *Microbiological analysis:* Alanio, Dellièvre, Bretagne

32 *Acquisition, analysis, or interpretation of data:* All authors.

33 *Drafting of the manuscript:* Alanio, Mégarbane, Bretagne

34 *Critical revision of the manuscript for important intellectual content:* All authors.

35 Dr Alanio had full access to all of the data in the study and takes responsibility for the integrity of the data and the
36 accuracy of the data analysis.

37

38 **Conflict of Interest Disclosures:** None reported.

39 **Funding:** The case investigations, analysis, and manuscript preparation were completed as part of official duties
40 at the university hospital.

41 **Acknowledgment:** The authors would like to thank Mrs. Alison Good (Scotland, UK) for her helpful review of
42 the manuscript. We would also like to thank our team who managed all COVID-19 patients and our lab technical
43 staff who performed pneumocystis RTqPCR on COVID-19 positive specimens.

44 **Keywords:** COVID-19; pneumocystosis; *Pneumocystis jirovecii*

45 **Word count:** 1000 words + 10 references + 1 table + 1 Figure

46 *To the Editor:*

47 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is spreading pandemically with more than
 48 3,500,000 diagnosed cases and 250,000 fatalities reported on May 07th 2020
 49 (<https://coronavirus.jhu.edu/map.html>). Approximately 5-10% of coronavirus disease 2019 (COVID-19)
 50 patients may require intensive care unit (ICU) management including mechanical ventilation and 30% may
 51 develop secondary pneumonia without identified etiology (1). Hospital-acquired bacterial or fungal
 52 superinfections, as described in critically ill patients with Influenza virus, can be suspected (2). Since
 53 pneumocystosis is usually reported in patients with T-cell immunodepression (3), less attention has been
 54 paid to *Pneumocystis jirovecii* in non-immunocompromised ICU patients although it accounts for 7% of
 55 the co-infections reported in those admitted with Influenza (4). Interestingly, COVID-19 patients may
 56 develop acute respiratory distress syndrome (ARDS) requiring adjunctive steroids or other
 57 immunomodulatory therapies, a well-known susceptibility factor for developing pneumocystosis (4). Here,
 58 we investigated the prevalence of *P. jirovecii* acid nucleic detection in respiratory specimens sampled to
 59 identify co-infections in COVID-19 patients admitted to the ICU.

60

61 **Methods**

62 All consecutive patients admitted to the ICU between March 15th and April 15th 2020 were enrolled. This
 63 study was part of the French COVID-19 cohort registry conducted by the REACTing consortium (REsearch
 64 and ACTion targeting emerging infectious diseases) and directed by INSERM (Institut national de la santé
 65 et de la recherche médicale) and ISARIC (International Severe Acute Respiratory and Emerging Infection
 66 Consortium). Our institutional ethics committee approved the study (IDRCB, 2020-A00256-33; CPP, 11-
 67 20 20.02.04.68737). When possible, signed informed consent was obtained from the patients or the next of
 68 kin.

69 Upon reception in the laboratory, all specimens including bronchoalveolar lavage (BAL) fluids and dTT-
 70 treated aspirations (dTT 1X at 37°C for 15min) were centrifuged, suspended in 200µL of water and
 71 submitted to extraction (whole nucleic acids extraction) using the GeneLead VIII extractor-thermocycler™
 72 (Precision System Science, Matsudo, Japan). *P. jirovecii* reverse transcriptase quantitative PCR (RTqPCR)

was performed to amplify mtSSU and mtLSU RNA and DNA of *P. jirovecii* using the new R-DiaPnJ kit™ (Diagenode, Liege, Belgium). β-D-glucan was tested using the Fungitell kit™ (Cape Cod Inc, Falmouth, US) as recommended by the manufacturer. Data are presented as median [range] or percentages as appropriate. Comparisons were performed using Mann-Whitney or exact Fisher tests as required. $P < 0.05$ was considered as significant.

Results

Twenty-nine successive COVID-19 patients (M/F sex ratio, 2.6; age, 60 years [33-80]) with the usual risk factors for severe COVID-19 presentation were included (Table1). All patients except one were intubated on admission. Twenty-seven patients (93%) who developed ARDS received corticosteroids once mechanically ventilated. Respiratory samples included 27 BALs (93%) and two bronchial aspiration fluids (7%). In 5/29 patients (17%), *P. jirovecii* RTqPCR was positive. The median quantitative cycle value was 32.4 [28.9-36.5].

No significant differences were observed between *P. jirovecii* RTqPCR-positive and negative patients in terms of age, risk factors for severe COVID-19 including prior steroid therapy, severity of ARDS, viral load, blood lymphocyte count, time between intubation or onset of symptoms and SARS-CoV2 detection and time between onset of symptoms, intubation or SARS-CoV2 detection and respiratory specimen sampling. Interestingly, the proportion of macrophages in BAL fluids was significantly higher in *P. jirovecii* RTqPCR-positive versus negative patients ($P = 0.003$; Figure1), by contrast to the proportions of neutrophils and lymphocytes.

Three out of five *P. jirovecii* RTqPCR-positive patients received co-trimoxazole as prophylaxis. To date, one patient has died, one patient is still mechanically ventilated and the three others including the two patients who were not treated with co-trimoxazole have been discharged from the hospital.

Discussion

We found an unexpectedly high proportion of critically ill COVID-19 patients detected with *P. jirovecii* (17%) as compared to previous findings in influenza patients (~7%) (4).

The presence of *P. jirovecii* in the healthy adult population has been measured using oropharyngeal wash samples obtained by gargling and examined by conventional or nested PCR methods.⁵ However, experts agree that the reported prevalence (~20%) has been overestimated due to technical issues such as contamination with amplicons responsible for false positives (3). In our experience using qPCR, around 15% of BAL fluids are positive in immunocompromised patients (3), supporting the proposal that the prevalence we observed in the apparently non-immunocompromised COVID-19 patients is actually elevated. These patients mostly exhibit marked lymphopenia and alterations in lymphocyte functions (6), likely explaining the high-rate of *P. jirovecii* detection. Nevertheless, β -D-glucan concentrations measured in the respiratory fluid specimens obtained in our five *P. jirovecii* RTqPCR-positive patients were lower than 120pg/mL supporting limited fungal loads in the lung alveoli (7). Of note, in two out of our nine tested *P. jirovecii* RTqPCR-negative patients, higher β -D-glucan concentrations (450 and 523pg/ml) lead to the diagnosis of putative invasive aspergillosis, another fungal infection of risk in COVID-19 patients (8).

Surprisingly, the BAL macrophage proportion was particularly elevated in our *P. jirovecii* RTqPCR-positive COVID-19 patients. In immunocompromised adults with pneumocystosis, BAL macrophage proportions of ~45% have been reported (9). Interestingly, in non-HIV patients, the count and proportion of BAL macrophages was significantly increased in mild compared to severe pneumocystosis, i.e. 40.7% versus 28.3% and 76 versus 50cells/ μ L, respectively (10). Taken together, these findings strengthen the hypothesis that *P. jirovecii* presence in the deep lung may influence local immunity and enhance inflammation.

Here, three out of five *P. jirovecii* RTqPCR-positive patients received co-trimoxazole as prophylactic regimen, based on the treating physician's decision. Whether a positive result should be an indication to consider administering co-trimoxazole, at least at prophylactic dosage in COVID-19 patients remains questionable.

Our study limitations include the relatively small number of patients, the single-center setting, and the short study period. However, to the best of our knowledge, this is the first study evaluating the prevalence of *P. jirovecii* in COVID-19 patients. Because we focused on critically ill COVID-19 patients, prevalence of *P. jirovecii* in less severe patients remains to be determined.

127 In conclusion, based on our findings, we advocate systematically searching for *P. jirovecii* in deep
 128 respiratory specimens in critically ill COVID-19 patients. We believe that this strategy may be useful in
 129 limiting enhanced inflammation due to the presence of *P. jirovecii* in the lung and avoiding inter-patient *P.*
 130 *jirovecii* transmission.

131

132 **Author disclosure**

133 The authors declare no conflict of interest

134

135

136 **Figure 1.** Distribution of the proportion of macrophages in the bronchoalveolar lavage (BAL) with positive or
 137 negative *Pneumocystis jirovecii* reverse transcriptase quantitative PCR (PjRTqPCR)

138

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
2. Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, *et al.* Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. *Lancet Respir Medicine* 2018;6:782-792.
- 3- Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, *et al.* ECIL guidelines for the diagnosis of *Pneumocystis jirovecii* pneumonia in patients with haematological malignancies and stem cell transplant recipients. *J Antimicrob Chemother* 2016;71:2386-2396.
4. Beumer MC, Koch RM, van Beuningen D, OudeLashof AM, van de Veerdonk FL, Kolwijck E, *et al.* Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. *J Crit Care* 2019;50:59-65.
5. Medrano FJ, Montes-Cano M, Conde M, de la Horra C, Respaldiza N, Gasch A, *et al.* *Pneumocystis jirovecii* in general population. *Emerg Infect Dis* 2005;11:245-250.
6. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, *et al.* Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* 2020;55:102763.
7. Theel ES, Doern CD. β -D-glucan testing is important for diagnosis of invasive fungal infections. *J Clin Microbiol* 2013;51:3478-3483.
8. Koehler P, Cornely OA, Böttiger BW, Duse F, Eichenauer DA, Fuchs F, *et al.* COVID-19 Associated Pulmonary Aspergillosis. *Mycoses* 2020. DOI: 10.1111/myc.13096.
9. Gaborit BJ, Tessoulin B, Lavergne RA, Morio F, Sagan C, Canet E, *et al.* Outcome and prognostic factors of *Pneumocystis jirovecii* pneumonia in immunocompromised adults: a prospective observational study. *Ann Intensive Care* 2019;9:131.

162 10. Lee JY, Park HJ, Kim YK, Yu S, Chong YP, Kim SH, *et al.* Cellular Profiles of Bronchoalveolar Lavage Fluid
 163 and Their Prognostic Significance for Non-HIV-Infected Patients with Pneumocystis jirovecii Pneumonia. *J Clin*
 164 *Microbiol* 2015;53:1310–1316.

165

Table 1. Characteristics of twenty-nine critically ill COVID-19 patients according to *Pneumocystis jirovecii* detection in the respiratory samples

Parameters	<i>P. jirovecii</i> RTqPCR- positive patients (n=5)	<i>P. jirovecii</i> RTqPCR- negative patients (n=24)	<i>P Value</i>
Age (years)	59 [41-79]	60 [33-80]	0.64
Gender (M/F)	1.5	3	0.60
Diabetes, N (%)	1 (20)	10 (42)	0.62
Hypertension, N (%)	3 (60)	11 (46)	0.65
Obesity, N (%)	0	7 (29)	0.30
Ischemic heart disease, N (%)	1 (20)	5 (21)	0.99
Prior steroid therapy, N (%)	2 (40)	2 (8)	0.13
PaO ₂ /FiO ₂ (mmHg)	167 [79-290]	162.5 [42-480]	0.59
Time from symptom start to SARS-CoV2 detection (days)	7 [4-13]	7.5 [3-30]	0.92
Time from symptom start to tracheal intubation (days)	8 [5-16]	8 [3-33]	0.72
Time from tracheal intubation to BAL (days)	1 [0-5]	3 [0-20]	0.25
Lymphocyte count (G/L)	0.8 [0.3-1.5]	1.1 [0.3-2.8]	0.99
BAL macrophages, N (%)	53 [49-72]	26 [4-46]	0.0003
BAL neutrophils, N (%)	23.5 [10-32]	46 [3-87]	0.29
BAL lymphocytes, N (%)	18 [10-39]	23 [1-74]	0.83
β-D-glucan (pg/mL) (N=13)	16.3 [7.0-105.0]	13.1 [7.8-523.0]	0.60
Viral load, (cycle)	23 [17-32]	28 [15-37]	0.34
Steroid administration in the ICU, %†	4 (80)	17 (71)	0.99
Outcome (death / in ICU / discharged), N (%)	1 (20) / 1 (20) / 3 (60)	9 (38) / 3 (12) / 12 (50)	0.1

BAL, bronchoalveolar lavage; ICU, intensive care unit; RTqPCR, reverse transcriptase quantitative polymerase chain reaction;

†Steroid regimen, dexamethasone intravenous dose of 20 mg once daily from day 1 to day 5, followed by 10 mg once daily from day 6 to day 10.